scholarly journals Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus

2014 ◽  
pp. 799
Author(s):  
Tatsuya Ishikawa ◽  
Mori ◽  
Niinuma ◽  
Nakamura ◽  
Matsuura ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Channel Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Additive Effects ◽  
Angiotensin Ii Receptor ◽  
Long Evans

scholarly journals ANALYSIS OF THE USE OF VARIOUS ANTIHYPERTENSIVE AGENTS IN PATIENTS WITH ARTERIAL HYPERTENSION, CONCOMITANT TYPE 2 DIABETES MELLITUS AND OBESITY (LITERATURE REVIEW AND OWN DATA)

2021 ◽  
Vol 2 (4(68)) ◽  
pp. 20-25
Author(s):  
I. Dunaieva
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Antihypertensive Agents ◽  
Individual Risk ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

Treatment of patients with arterial hypertension with diabetes and obesity requires taking into account the individual risk of complications and the use of appropriate differentiated tactics, and therefore the appointment of complex treatment with drugs that inhibit excessive activation of the renin-angiotensin-aldosterone system, in particular angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, is the most appropriate and justified. Thus, a comparative analysis of the use of various treatment regimens in patients with arterial hypertension, concomitant type 2 diabetes mellitus and obesity was carried out using the angiotensinconverting enzyme inhibitor ramipril and the angiotensin II receptor blocker telmisartan. The inclusion of ramipril or telmisartan in standard therapy has been shown to have a positive effect on the structural and functional parameters of the left ventricle and ejection fractions. Also, at the same time, the neutral effect of these drugs on carbohydrate and improvement of some components of lipid metabolism in the examined category of patients was determined.

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

2006 ◽  
Vol 34 (3) ◽  
pp. 297-302 ◽  
Author(s):  
F Yu ◽  
T Takahashi ◽  
J Moriya ◽  
K Kawaura ◽  
J Yamakawa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Obese Mice ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonist ◽  
Alcoholic Fatty Liver ◽  
Adiponectin Mrna

We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg ( n = 5) or placebo ( n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document